title: Sorafenib inhibits ABCG2 and overcomes irinotecan resistance--letter.
authors.affiliation: Corresponding Author: Malcolm A. Smith, National Cancer Institute, 9609 Medical Center Drive, Room 5-W414, MSC 9737, Bethesda, MD 20892 (for U.S. Postal Service Delivery), Rockville, MD 20850 (for non-USPS courier delivery and campus visits). Malcolm.Smith@nih.gov.
authors.forename: Malcolm A
authors.initials: MA
authors.lastname: Smith
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000235:genetics*; D000818:Animals; D002166:Camptothecin / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics*; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000008:administration & dosage*
chemical_list: D018528:ATP-Binding Cassette Transporters; D009363:Neoplasm Proteins; D010671:Phenylurea Compounds; D009536:Niacinamide; D002166:Camptothecin